The STEM™ Platform
Proven Results from STEM™
Published in Cell Reports, Antibody Therapeutics, J Biol Chem
How STEM™ Works
Computational Library Design
Advanced algorithms analyze your lead antibody and design targeted diversity across CDR and framework positions, maximizing functional coverage while maintaining structural integrity.
High-Diversity Library Construction
Our patented WizAmp™ cloning method captures >1010 unique variants per round — orders of magnitude beyond traditional methods — ensuring rare, high-performing clones are represented.
Multi-Parameter Selection
Phage display selection screens simultaneously for affinity, specificity, expression, and developability. Stability and polyspecificity counter-selections remove problematic clones early.
Iterative Enhancement
Top candidates seed the next round of diversification. Each stage builds on previous gains, achieving cumulative improvements that single-pass methods cannot match.
Key Advantages Over Alternative Approaches
vs. AI-Only Modeling
AI predictions are limited by training data and cannot fully account for real-world biophysical constraints. STEM™ validates computationally designed diversity through actual functional selection, ensuring every candidate is experimentally proven.
vs. Yeast Display
Yeast display cannot integrate developability selection into the screening process. STEM™ enables direct stability and polyspecificity counter-selections during phage panning, eliminating undevelopable candidates before they consume downstream resources.
vs. CDR Walking
Traditional CDR walking optimizes one region at a time and misses synergistic mutations. STEM™ diversifies all relevant positions simultaneously and captures combinatorial improvements that sequential approaches cannot access.
vs. B-cell / Hybridoma Methods
B-cell and hybridoma approaches only sample a fraction of the immune repertoire. Our patented library construction uniformly amplifies all antibody genes, capturing rare high-affinity clones that competitor methods miss entirely.
Applications
Affinity Maturation
Achieve picomolar KD values from micromolar starting points. Multi-stage selection yields >1,300-fold improvements while maintaining specificity and developability.
Learn more →Antibody Humanization
Our patent-pending approach humanizes both CDR and framework regions simultaneously, reducing immunogenicity risk while improving function.
Learn more →Developability Optimization
Integrated stability selection and polyspecificity counter-screening during phage panning removes undevelopable candidates before they consume downstream resources.
Learn more →pH-Sensitive Engineering
Engineer pH-dependent binding for recycling antibodies and enhanced target clearance. STEM™ selects for optimal pH-sensitive release while preserving high-affinity target engagement.
Inquire →Expression Optimization
Selection pressure for high expression is built into every STEM™ round, yielding therapeutic leads that are not only potent but also manufacturable at commercial scale.
Inquire →Multi-Specific Engineering
Optimize individual arms of bispecific or multi-specific constructs. STEM™ can balance affinity across multiple targets while maintaining favorable biophysical properties.
Inquire →100% Client IP Ownership — No Royalties
All engineered antibodies and associated IP are fully owned by you. We operate as a fee-for-service partner with no milestone payments, royalties, or equity requirements. Your program, your molecules, your future.
Ready to Accelerate Your Antibody Program?
Our scientists have optimized antibodies against dozens of therapeutic targets. Let us show you what STEM™ can do for your lead candidates.
Request a Consultation → View Case Studies